This is why I want Anavex to remain retail dominated and I think Missling does too. Retail is more likely to let Missling put the patients and the science first, the Street Walkers don't give a damn.
BIIB themselves do not get any dollars out of a share price hike. Insiders might if they sell and those external parties on the right side of the trade.